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Liver X receptors (LXRs) are nuclear receptors that function as ligand-activated transcription factors regulating lipid
metabolism and inflammation. Recent discoveries found LXRs could regulate tumor growth in a variety of cancer
cell lines. In this study, we investigated the effect of LXR activation on melanoma cell proliferation and apoptosis
both in vitro and in vivo. Treatment of B16F10 and A-375 melanoma cells with synthetic LXR agonist T0901317
significantly inhibited the proliferation of melanoma cells in vitro. Meanwhile, T0901317 induced the apoptosis of
B16F10 melanoma cells in a dose-dependent manner. Furthermore, western blot assay showed that the pro-apoptotic
effect of T0901317 on B16F10 melanoma cells was mediated through caspase-3 pathway. Oral administration of
T0901317 inhibited the growth of B16F10 melanoma in C56BL/6 mice. Altogether, this study demonstrates the critical
role of LXRs in the regulation of melanoma growth and presents the LXR agonist T0901317 as a potential
anti-melanoma agent.
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Melanoma is one of the most notoriously aggressive and
treatment-resistant of human cancers, causing the major-
ity (75%) of deaths related to skin cancers [1]. Although
surgical excision remains to be a standard treatment at
the early stages of the disease, it is ineffective after metas-
tasis and patients with advanced disease have a poor prog-
nosis [2]. Novel anti-cancer drugs and therapies are
urgently needed to prevent and treat melanoma.
Liver X receptors (LXRα/NR1H3 and LXRβ/NR1H2)
are nuclear receptors that could be activated by natural
ligands like oxysterols, as well as synthetic agonists such
as T0901317 [3]. High levels of LXRα expression can be
found in liver, kidney, intestine, fat tissue and macro-
phages, while expressions of LXRβ are ubiquitous [4].
LXR agonists have been shown to be effective in treating
cardiovascular diseases, metabolic syndromes, and murine
models of atherosclerosis, diabetes and Alzheimer’s disease
[5-8]. Recently, studies also show that LXR agonists exhibit
anti-cancer activities in a variety of cancer cell lines. For ex-
ample, LXR agonist T0901317 suppressed the proliferation* Correspondence: drjianghua@yeah.net
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unless otherwise stated.of prostate, breast, colon, ovarian and leukemia cancer cells
in vitro [9], and oral administration of T0901317 inhibited
the growth of LNCaP tumors in C56BL/6 mice [10]. How-
ever, whether LXR agonist treatment could inhibit melan-
oma cell proliferation both in vitro and in vivo, and the
underlying mechanisms, remain elusive.
Based on the previously reported anti-cancer activities of
LXR agonists in multiple cancer cell lines, in this study, we
sought to explore the effect of LXR agonist on B16F10 and
A-375 melanoma cells and determine whether LXRs can
be developed as a potential target in melanoma therapy.Materials and methods
Reagents
Synthetic LXR agonist T0901317 was purchased from
Cayman Chemical (Cayman Chemical, Ann Arbor, MI,
USA). T0901317 used in the cell culture were diluted in
DMSO (Sigma, Saint Louis, MO, USA). For xenograft
model experiment, T0901317 was diluted in sesame oil
(Sigma, Saint Louis, MO, USA) as previously reported
[10]. caspase-3, cleaved caspase-3, actin antibodies were
purchased from Cell Signaling Technology (Beverly, MA,
USA).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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B16F10 murine melanoma cell line, A-375 human melan-
oma cell line and murine melanocyte cell line L10BIOBR
were obtained from Cell Bank, Shanghai Institute of Life
Science, Chinese Academy of Sciences (Shanghai, China).
Cell lines were grown and maintained in DMEM supple-
mented with 10% fetal bovine serum (FBS) and antibiotics
(100 U/mL penicillin and 10 μg/mL streptomycin) in a
humidified incubator with 5% carbon dioxide, at 37°C.
Transfection of siRNA
The siRNA oligonucleotides against mouse LXRα, LXRβ,
and control were purchased from Santa Cruz Biotech-
nology. B16F10 cells were transfected with siRNA oli-
gonucleotides using GenJet transfection reagent (Signa
Gen, Gaithersburg, MD) according to the manufac-
turer’s instructions.
Reverse transcription-PCR and quantitative PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. cDNA was
synthesized with PrimeScript RT Master Mix (TAKARA,
Dalian, China) according to the manufacturer’s instruc-
tions. The quantitative PCR was performed using SYBR
Green PCR mix (Roche, Mannheim, Germany) on an ABI
Prism 7900HT (Applied Biosystems). Thermocycler con-
ditions included 2-minute incubation at 50°C, then 95°C
for 10 minutes; this was followed by a 2-step PCR pro-
gram, as follows: 95°C for 15 seconds and 60°C for 60 sec-
onds for 40 cycles. β-actin was used as an internal control
to normalize for differences in the amount of total RNA
in each sample. The primer sequences were as follows (in
the 5′ to 3′ orientation): β-actin forward, TGTCCAC
CTTCCAGCAGATGT, β-actin reverse, AGCTCAGTAA
CAGTCCGCCTAGA; ABCA1 forward, TACAGAAGC
CAAGAAGGACC, ABCA1 reverse, TCGTCAGAGGTT
TAAGTGGG; SREBF1 forward, TGGCTTGGTGATGCT
ATGTT, SREBF1 reverse, GGTTATTACCTGGTGGAG
GG. Relative levels of gene expression were determined
using the ΔΔCt method relative to the internal control
gene β-actin.
Cell proliferation assay
B16F10 and A-375 melanoma cells and murine melanocyte
cell line L10BIOBR were cultured in 96-well plate at an ini-
tial density of 2000 cells per well, in 100 μl of DMEM
medium containing 1% FBS with the addition of DMSO or
T0901317 (1, 3 and 10 μM). After 24, 48 and 72 hours of
DMSO or T0901317 treatment, cell proliferation was deter-
mined using a WST-1 Kit (Roche, Mannheim, Germany).
Cell apoptosis analysis
Murine B16F10 melanoma cells were cultured in DMEM
medium containing 10% FBS, and treated with DMSOor T0901317 (3 μM) for 24, 48 and 72 hours. Then, cells
were harvested by trypsinization, and stained with FITC
Annexin V and propidium iodide (PI) (Invitrogen, Paisley,
UK). The stained cells were analyzed immediately by flow
cytometry using FACS Calibur (BD Biosciences) and FlowJo
software.Western blot
Cells were lysed in RIPA buffer (Beyotime, Haimen,
China) and protein concentration was determined with
the Bradford reagent (Beyotime, Haimen, China) using a
bovine serum albumin standard. Proteins were resolved on
6% polyacrylamide gels containing SDS. Electrophoresis
and blotting were performed using standard procedures.
Visualization of the immunoreactive proteins was accom-
plished with an enhanced chemiluminescence reaction
(Millipore, Billerica, MA, USA). Measurement of actin ex-
pression was used as a loading control.Mouse xenograft model
Six- to eight-week-old male C57BL/6 mice were sub-
cutaneously injected with B16F10 melanoma cells at the
dose of 106 cells (n = 5 mice per group). Tumor growths
were monitored by caliper measuring every other day,
and tumor volumes were calculated using the formula:
length × (width)2 × 0.52. The liver X receptor agonist T0
901317 was administered by daily oral gavage in a ses-
ame oil vehicle as previously reported [10]. All the mice
were sacrificed and tumors were harvested for further
analysis at indicated time points. Mice were treated and
maintained at the Center for Laboratory Animals, Sec-
ond Military Medical University.Statistical analysis
All experiments were repeated at least three times. Data
were expressed as mean ± SEM. Statistical significance
was determined by two-way analysis of variance followed
by Student t test. Values of p less than 0.05 were consid-
ered significant.Results
LXR expression in murine melanoma cell line
To study the role of LXRs in melanoma development, we
first investigated the expressions of LXRs (LXRα and LXRβ)
in B16F10 murine melanoma cell line and murine melano-
cyte cell line L10BIOBR using reverse transcription-PCR.
As shown in Figure 1A, both LXRα and LXRβ were
expressed in B16F10 cells. However, expressions of LXRα
and LXRβ were not detected in L10BIOBR. Upon T090
1317 treatment, expressions of LXR target genes, ABCA1
and SREBF1, were induced in B16F10 (Figure 1B), indicat-
ing LXRs were functional in B16F10 melanoma cell line.
Figure 1 Expressions of LXRs in B16F10 melanoma cells. (A) Reverse transcription-PCR analysis of LXRα and LXRβ expression in B16F10 melanoma
cells and melanocyte cell line L10BIOBR. (B) Real-time PCR analysis of expressions of LXR target genes (ABCA1 and SREBF1) in B16F10 melanoma cells
upon T0901317 treatment. B16F10 melanoma cells were treated with DMSO or T0901317 (10 μM) for 48 hours. *P < 0.05, **P < 0.01.
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As previously reported, LXR agonists are able to inhibit
the proliferation of a variety of cancer cell lines. To de-
termine the effect of LXR agonists on melanoma cell
proliferation, we treated melanoma cell line B16F10 and
A-375 with synthetic agonist T0901317. As determined
by WST-1 assay, T0901317 suppressed the proliferation of
B16F10 melanoma cell line in a dose- and time-dependent
manner (Figure 2A, B). However, normal melanocyte pro-
liferation was not affected by T0901317 (Figure 2C).
To test the specificity of LXRs in T0901317-mediated
effects, we used small interfering RNAs (siRNAs) to down
regulate the expression of LXRα and LXRβ in B16F10 cells.
Although knockdown of LXRα did not reverse the anti-
proliferative effects of T0901317, T0901317 failed to mani-
fest the anti-proliferative effects in the absence of LXRβ
(Figure 2D). Therefore, LXR activation by T0901317, expe-
cially LXRβ, inhibits proliferation of melanoma cells.
LXR activation induces apoptosis of melanoma cells via
caspase pathway
Based on the anti-proliferation effects of LXR activation on
melanoma cells, we then investigated the effect of LXR
agonist T0901317 on melanoma cell apoptosis. B16F10 cells
were treated for 72 hours with increasing doses of T09
01317, and then collected for apoptosis assay. As shown in
Figure 3A, compared with DMSO treatment, T0901317
treatment significantly increased the percentage of apop-
totic Annexin V+ PI− cells, with 10 μM T0901317 exhibit-
ing the strongest pro-apoptotic effects.
To further understand the mechanisms by which LXR
activation promotes B16F10 cell apoptosis, we examined
the expressions of apoptotic pathway-associated proteins.
As shown in Figure 3B, T0901317 treatment induced theactivation of caspase-3, indicating caspase-3 was involved
in the LXRs-regulated melanoma apoptosis.
LXR activation inhibits tumor growth in mice
To confirm the anti-cancer effect of LXR agonist T090
1317 in vivo, we established the murine melanoma xeno-
graft model and treated mice with LXR agonist T0901317
simultaneously. T0901317 was administered via gavage
using sesame oil vehicle at a dose of 10 mg/kg body weight
per day as previously reported [10]. As shown in Figure 4A,
the tumor volumes of T0901317-treated mice were signifi-
cantly reduced when compared to vehicle-treated mice.
To further confirm the in vivo anti-melanoma activity of
T0901317 was mediated through LXR signaling, we ana-
lyzed the expression of LXR target genes, ABCA1 and
SREBF1, in tumors, and found that expressions of ABCA1
and SREBF1 were increased in T0901317-treated melan-
oma (Figure 4B).
Discussion
In this report, we present evidence of an anti-tumor effect
for LXRs in a melanoma cancer system. Coupled with
others’ results in prostate cancer, breast cancer, ovarian
cancer, leukemia, hepatoma, non-small lung cancer and
colon cancer cells [4,9,11], these data suggest that LXRs
could inhibit tumor growth in multiple cancer systems.
Malignant melanoma is the most aggressive of the cuta-
neous malignancies [12], as current therapeutic treatments
are greatly inadequate. Presently, the only effective therapy
is the wide surgical resection of localized melanoma in its
primary stages [13] and it is usually resistant to cytotoxic
chemotherapy. Therefore, investigating the mechanisms of
melanoma development and exploring novel drugs to treat
melanoma are becoming more and more urgent.
Figure 2 LXR activation inhibits proliferation of melanoma cells. (A) B16F10 melanoma cells were treated with increasing concentrations of
T0901317 for 0, 24, 48 and 72 hours and tested for proliferation. (B) A-375 melanoma cells were treated with increasing concentrations of
T0901317 for 0, 24, 48 and 72 hours and tested for proliferation. (C) L10BIOBR cells were treated with 10 μM T0901317 for 72 hours and tested for
proliferation. (D) B16F10 cells were transfected with siRNA oligonucleotides. RT-PCR analysis was performed after 48 hours, and proliferation of
B16F10 was measured after 72 hours in the presence of T0901317. *P < 0.05.
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tional programs that integrate the homeostatic control of
almost all biological processes [14]. LXRs are nuclear re-
ceptors that regulate lipid metabolism and inflammation
[15]. Recently, LXRs were found to regulate the cancer de-
velopment, and LXR agonists were found to be able to
suppress the proliferation of multiple types of cancer cells,
such as prostate cancer, breast cancer, ovarian cancer,
leukemia, hepatoma, non-small lung cancer, colon cancer
cells and so on [9]. Though Chuu et al. found that LXR
agonists implicated antiproliferative effect on human
melanoma cell line MDA-MB-435 [9], the mechanisms
were elusive and whether LXR agonists could inhibit
melanoma growth in vivo remains unknown. In our study,
we found that synthetic LXR agonist T0901317 also sup-
pressed the proliferation of B16F10 and A-375 melanoma
cells both in vitro and in vivo, suggesting the critical role
of LXRs in controlling melanoma progression and pre-
senting LXR agonist as a potential anti-melanoma agent
in the future.
Besides the anti-melanoma effects of LXRs, others have
also reported that LXRs might have important biological
roles in the skin. For example, LXRs could induce lipidsynthesis in sebocytes, and inhibit the expressions of cyto-
kines and metalloproteinases in skin-photoaging models
[16-18]. LXRs are upregulated in melanocytes from perile-
sional skin of vitiligo patients [19], and LXR activation
could inhibit the melanogenesis in human primary melano-
cytes and murine B16 melanoma cells by downregulating
melanogenic enzymes through Ras- and ERK-induced
MITF degradation [20]. Our study presented LXRs as key
target proteins for the treatment of melanoma, which does
not conflict others’ finding, depending on the use of differ-
ent agonist and dosages. Further study is needed to fully
explore the role of LXRs in the skin, including lipid syn-
thesis, skin photoaging, melanogenisis as well as melan-
oma growth.
Up to now, the exact mechanisms by which LXR exerts
anti-tumor effects are not clear. However, according to a
previous study on LXR, LXR might exert anti-tumor ef-
fects through downregulation of AKT phosphorylation
and inducing the canonical apoptotic pathway in prostate
cancer [11]. It is possible that, in our study, LXR might
also exert anti-melanoma effects through AKT signalling.
In our future study, we will try to explore the molecular
mechanisms.
Figure 4 Effect of T0901317 on melanoma growth in C56BL/6 mice. (A) B16F10 melanoma cells (106) were injected subcutaneously into
flanks of the mice. The liver X receptor agonist T0901317 (10 mg/kg) or sesame oil vehicle was administered by daily oral gavage. Tumor growths
were monitored every 3 days. (B) Expressions of LXRs target genes (ABCA1 and SREBF1) in tumor samples were analyzed by real-time PCR at day
15 when mice were sacrificed. *P < 0.05, **P < 0.01.
Figure 3 LXR activation induces apoptosis of B16F10 melanoma cells via the caspase 3 pathway. B16F10 melanoma cells were treated
with DMSO or different dosage of T0901317 for 72 hours. (A) Cells were harvested and Annexin V/PI assays were performed to determine the
effect of T0901317 on cell apoptosis by FACS. (B) Percentage of Annexin V+PI- cells depicted in A was quantified. (C) Cells were harvested and
expressions of caspase-3 were detected. Measurement of actin expression was used as a loading control. *P < 0.05, **P < 0.01.
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http://www.cancerci.com/content/14/1/16In this study, we demonstrated that LXR activation
inhibited the proliferation, and induced the apoptosis of
melanoma cells. We proposed that synthetic agonist of
LXRs, T0901317, might be a potential agent in treating
melanoma.
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